"Mammogen...is set to present groundbreaking clinical data at the 2023 San Antonio Breast Cancer Symposium (SABCS). The poster, titled 'Development of a plasma-based real-time qPCR gene expression assay for targeted screening and diagnosis of early-stage breast cancer,' showcases the strength and innovation of Mammogen's proprietary genTRU-breast clinical assay."
"Mammogen...has announced the successful completion of Clinical Laboratory Improvement Amendments (CLIA) validation for its pioneering plasma-based clinical assay, genTRU-breast, a test designed to detect the earliest stages of breast cancer. This achievement represents a momentous step forward in revolutionizing breast health."